Table 1.
Patient, tumor, and treatment characteristics
| Number of patients | 108 |
| Age (mean ± SD) years | 64.3 ± 12.3 |
| Male sex, n (%) | 67 (62%) |
| Primary tumor, n (%) | |
| Right‐sided | 19 (17.6%) |
| Transverse | 7 (6.5%) |
| Left‐sided | 46 (42.6%) |
| Rectum | 36 (33.3%) |
| KRAS mutated | 42/96 (43.8%) |
| N + status | 75 (69.4%) |
| Stage III–IV | 81 (75%) |
| Chemotherapy for primary tumor, n (%) | |
| Neoadjuvant | 42 (38.8%) |
| Adjuvant | 56 (51.9%) |
| CRLM, n (%) | |
| Synchronous < 12 months after primary tumor | 74 (68.5%) |
| Number of LM, median (IQR) | 2 (4) |
| Size of the largest CRLM (mm), median (IQR) | 29 (25) |
| Size of the largest CRLM > 50 mm, mean (%) | 26 (24.1%) |
| CEA (ng/ml), median (IQR) | 15 (31) |
| CEA > 200 ng/ml, n (%) | 11 (10.2%) |
| Clinical risk score, n (%) | |
| 0 | 4 (3.7%) |
| 1 | 15 (13.9%) |
| 2 | 38 (35.2%) |
| 3 | 38 (35.2%) |
| 4 | 10 (9.3%) |
| 5 | 3 (2.8%) |
| Low risk (0–2) | 57 (52.8%) |
| High risk (3–5) | 51 (47.2%) |
| Metabolic chracteristics CRLM | |
| SUVmax/SUVmean(liver), median (IQR) | 3.9 (2.3) |
| SUVmax/SUVmean(liver) > 4.3, n (%) | 46 (42.6%) |
| Metabolic Clinical Risk Score, n (%): | |
| 0 | 4 (3.7%) |
| 1 | 10 (9.3%) |
| 2 | 26 (24.1%) |
| 3 | 40 (37%) |
| 4 | 19 (17.6%) |
| 5 | 6 (5.6%) |
| 6 | 3 (2.8%) |
| Low risk (0–3) | 80 (74.1%) |
| High risk (4–6) | 28 (25.9%) |
| Liver surgery, n (%): | |
| Portal vein embolization | 13 (12%) |
| Two‐steps hepatectomy | 19 (17.6%) |
| Major hepatectomy | 53 (49.1%) |
| Complication clavien Dindo, n (%) | |
| 0 | 64 (59.3%) |
| I | 10 (9.3%) |
| II | 12 (11.1%) |
| IIIa | 17 (15.7%) |
| IVa | 5 (4.6%) |
| V | 0 |
| Chemotherapy for CRLM, n (%): | |
| Preoperative | 85 (78.7%) |
| Postoperative | 17 (15.7%) |
| HGP CRLM, n (%): | |
| DHGP | 22 (20%) |
| non‐DHGP | 86 (80%) |
Abbreviations: CEA, carcino embryonic antigen; CRLM, colorectal liver metastasis; DHGP, pure desmoplastic histologic growth pattern; HGP, histologic growth pattern; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; LM, liver metastasis; N+, lymph node; non‐DHGP, nondesmoplastic histologic growth pattern; SUV, standardized uptake values.